Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-malarials most effective in lupus patients genetically at risk of high levels of TNF-alpha

13.02.2006


Anti-malarial drugs are most effective in people with lupus who are genetically predisposed to high levels of tumour necrosis factor alpha and low levels of the cytokine IL-10. A study published today in the journal Arthritis Research & Therapy reveals that anti-malarial drugs, widely used to treat systemic lupus erythematosus (SLE), bring serum levels of tumour necrosis factor alpha (TNF-alpha) back to normal in SLE patients. The research shows that these drugs are more effective in patients who have two specific genetic variations (polymorphisms) on the TNF-alpha and IL-10 genes that predispose them to abnormally high levels of TNF-alpha and low levels of the cytokine IL-10. This finding may have important clinical applications through the identification of lupus patients who are the most likely to benefit from anti-malarial therapy.



Patricia Lopez, from the University of Oviedo in Spain and colleagues from the Hospital Universitario Central de Asturias in Oviedo matched 192 SLE patients with 343 healthy individuals to act as controls. The researchers genotyped both patients and controls for two specific polymorphisms on the TNF-alpha and IL-10 genes. Lopez et al. then measured TNF-alpha serum levels in 171 of the SLE patients and 215 of the controls. The patients were asked precise questions regarding any treatment received before the study.

Lopez et al.’s results show that, as expected, average TNF-alpha serum levels were higher in the population of SLE patients (33.57pg/ml) than in the group of controls (19.66 pg/ml). However, patients who had been taking anti-malarial drugs for at least three months before the study had serum levels of TNF-alpha (16.64 pg/ml) similar to those of controls. Patients who had not been taking the drugs before the study had much higher levels of TNF-alpha (60.78 pg/ml).


Lopez et al. found that, in patients with both polymorphisms, TNF-alpha levels were four times lower if the patient had been taking anti-malarial drugs. For patients who do not have the polymorphisms, the difference in TNF-alpha levels was much less significant between patients who were on anti-malarial therapy and patients who were not. Patients with both polymorphisms had a four times higher probability to respond well to anti-malarial therapy (and not need any other therapy) than other patients.

Juliette Savin | EurekAlert!
Further information:
http://www.biomedcentral.com

More articles from Life Sciences:

nachricht Scientists spin artificial silk from whey protein
24.01.2017 | Deutsches Elektronen-Synchrotron DESY

nachricht Choreographing the microRNA-target dance
24.01.2017 | UT Southwestern Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>